Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.

Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, Curhan GC, Ascherio A; Parkinson Study Group SURE-PD Investigators.

Neurology. 2019 Oct 1;93(14):e1328-e1338. doi: 10.1212/WNL.0000000000008194. Epub 2019 Sep 4.

PMID:
31484712
2.

Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.

Fischer DL, Auinger P, Goudreau JL, Paumier KL, Cole-Strauss A, Kemp CJ, Lipton JW, Sortwell CE.

Parkinsonism Relat Disord. 2018 Aug;53:70-75. doi: 10.1016/j.parkreldis.2018.05.003. Epub 2018 May 9.

PMID:
29759928
3.

Metabolism of Dopamine in Nucleus Accumbens Astrocytes Is Preserved in Aged Mice Exposed to MPTP.

Winner BM, Zhang H, Farthing MM, Karchalla LM, Lookingland KJ, Goudreau JL.

Front Aging Neurosci. 2017 Dec 12;9:410. doi: 10.3389/fnagi.2017.00410. eCollection 2017.

4.

Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.

Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC; NINDS NET-PD Investigators.

J Parkinsons Dis. 2017;7(1):117-127. doi: 10.3233/JPD-160965.

PMID:
27911341
5.

FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure.

Patterson JR, Kim EJ, Goudreau JL, Lookingland KJ.

Brain Res. 2016 Oct 15;1649(Pt A):53-66. doi: 10.1016/j.brainres.2016.08.030. Epub 2016 Aug 24.

6.

Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.

Goudreau JL, Pérez A, Aminoff MJ, Boyd JT, Burau KD, Christine CW, Leehey M, Morgan JC; NET-PD Investigators.

J Neurol Sci. 2016 Jul 15;366:74-81. doi: 10.1016/j.jns.2016.04.021. Epub 2016 Apr 16.

PMID:
27288780
7.

Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB1 and CB2 Cannabinoid Receptors.

Simkins TJ, Fried D, Parikh K, Galligan JJ, Goudreau JL, Lookingland KJ, Kaplan BL.

J Neuroimmune Pharmacol. 2016 Dec;11(4):669-679. Epub 2016 Jun 10.

PMID:
27287619
8.

Comparison of the structure, function and autophagic maintenance of mitochondria in nigrostriatal and tuberoinfundibular dopamine neurons.

Hawong HY, Patterson JR, Winner BM, Goudreau JL, Lookingland KJ.

Brain Res. 2015 Oct 5;1622:240-51. doi: 10.1016/j.brainres.2015.06.030. Epub 2015 Jul 2.

9.

Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase.

Tiernan CT, Edwin EA, Hawong HY, Ríos-Cabanillas M, Goudreau JL, Atchison WD, Lookingland KJ.

Toxicol Sci. 2015 Apr;144(2):347-56. doi: 10.1093/toxsci/kfv001. Epub 2015 Jan 19.

10.

Parkinson's disease severity and use of dopaminergic medications.

Fang JY, Pérez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL; NINDS NET-PD Investigators.

Parkinsonism Relat Disord. 2015 Mar;21(3):297-9. doi: 10.1016/j.parkreldis.2014.10.016. Epub 2014 Dec 15.

11.

The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.

Benskey MJ, Manfredsson FP, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2015 Jan;46:1-11. doi: 10.1016/j.neuro.2014.11.004. Epub 2014 Nov 20.

12.

Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity.

Simkins T, Crawford RB, Goudreau JL, Lookingland KJ, Kaplan BL.

J Neuroimmune Pharmacol. 2014 Sep;9(4):544-57. doi: 10.1007/s11481-014-9549-x. Epub 2014 May 29.

PMID:
24870806
13.

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K.

JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.

14.

Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein.

Benskey M, Lee KY, Parikh K, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2013 Jul;37:144-53. doi: 10.1016/j.neuro.2013.04.002. Epub 2013 May 1.

15.

The role of de novo catecholamine synthesis in mediating methylmercury-induced vesicular dopamine release from rat pheochromocytoma (PC12) cells.

Tiernan CT, Edwin EA, Goudreau JL, Atchison WD, Lookingland KJ.

Toxicol Sci. 2013 May;133(1):125-32. doi: 10.1093/toxsci/kft025. Epub 2013 Feb 19.

16.

Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification.

Hsu SC, Sears RL, Lemos RR, Quintáns B, Huang A, Spiteri E, Nevarez L, Mamah C, Zatz M, Pierce KD, Fullerton JM, Adair JC, Berner JE, Bower M, Brodaty H, Carmona O, Dobricić V, Fogel BL, García-Estevez D, Goldman J, Goudreau JL, Hopfer S, Janković M, Jaumà S, Jen JC, Kirdlarp S, Klepper J, Kostić V, Lang AE, Linglart A, Maisenbacher MK, Manyam BV, Mazzoni P, Miedzybrodzka Z, Mitarnun W, Mitchell PB, Mueller J, Novaković I, Paucar M, Paulson H, Simpson SA, Svenningsson P, Tuite P, Vitek J, Wetchaphanphesat S, Williams C, Yang M, Schofield PR, de Oliveira JR, Sobrido MJ, Geschwind DH, Coppola G.

Neurogenetics. 2013 Feb;14(1):11-22. doi: 10.1007/s10048-012-0349-2. Epub 2013 Jan 20.

17.

A call for transparent reporting to optimize the predictive value of preclinical research.

Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD.

Nature. 2012 Oct 11;490(7419):187-91. doi: 10.1038/nature11556.

18.

Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout mice.

Simkins TJ, Janis KL, McClure AK, Behrouz B, Pappas SS, Lehner A, Kaminski NE, Goudreau JL, Lookingland KJ, Kaplan BL.

J Neuroimmune Pharmacol. 2012 Sep;7(3):533-8. doi: 10.1007/s11481-012-9375-y. Epub 2012 May 27.

19.

Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression.

Benskey M, Behrouz B, Sunryd J, Pappas SS, Baek SH, Huebner M, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2012 Jun;33(3):321-31. doi: 10.1016/j.neuro.2012.02.001. Epub 2012 Feb 9. Erratum in: Neurotoxicology. 2012 Jun;33(3):406.

20.

Opioid-mediated regulation of A11 diencephalospinal dopamine neurons: pharmacological evidence of activation by morphine.

Pappas SS, Kennedy T, Goudreau JL, Lookingland KJ.

Neuropharmacology. 2011 Sep;61(4):614-21. doi: 10.1016/j.neuropharm.2011.05.002. Epub 2011 May 13.

21.

Neonatal androgen-dependent sex differences in lumbar spinal cord dopamine concentrations and the number of A11 diencephalospinal dopamine neurons.

Pappas SS, Tiernan CT, Behrouz B, Jordan CL, Breedlove SM, Goudreau JL, Lookingland KJ.

J Comp Neurol. 2010 Jul 1;518(13):2423-36. doi: 10.1002/cne.22340.

22.

Activation of autophagy through modulation of 5'-AMP-activated protein kinase protects pancreatic beta-cells from high glucose.

Han D, Yang B, Olson LK, Greenstein A, Baek SH, Claycombe KJ, Goudreau JL, Yu SW, Kim EK.

Biochem J. 2010 Jan 15;425(3):541-51. doi: 10.1042/BJ20090429.

PMID:
19903169
23.

Insulin withdrawal-induced cell death in adult hippocampal neural stem cells as a model of autophagic cell death.

Baek SH, Kim EK, Goudreau JL, Lookingland KJ, Kim SW, Yu SW.

Autophagy. 2009 Feb;5(2):277-9. Epub 2009 Feb 17.

PMID:
19158478
24.

Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease.

Janis KL, Brennan RT, Drolet RE, Behrouz B, Kaufman SK, Lookingland KJ, Goudreau JL.

J Alzheimers Dis. 2008 Sep;15(1):97-107.

PMID:
18780970
25.

Autophagic death of adult hippocampal neural stem cells following insulin withdrawal.

Yu SW, Baek SH, Brennan RT, Bradley CJ, Park SK, Lee YS, Jun EJ, Lookingland KJ, Kim EK, Lee H, Goudreau JL, Kim SW.

Stem Cells. 2008 Oct;26(10):2602-10. doi: 10.1634/stemcells.2008-0153. Epub 2008 Jul 24.

26.

Lack of D2 receptor mediated regulation of dopamine synthesis in A11 diencephalospinal neurons in male and female mice.

Pappas SS, Behrouz B, Janis KL, Goudreau JL, Lookingland KJ.

Brain Res. 2008 Jun 12;1214:1-10. doi: 10.1016/j.brainres.2008.03.010. Epub 2008 Mar 19.

PMID:
18462709
27.

Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult.

Behrouz B, Drolet RE, Sayed ZA, Lookingland KJ, Goudreau JL.

Neuroscience. 2007 Jul 13;147(3):592-8. Epub 2007 Jun 20.

28.

Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism.

Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A.

FASEB J. 2006 Nov;20(13):2302-12.

PMID:
17077307
29.

Medical management of advanced Parkinson's disease.

Goudreau JL.

Clin Geriatr Med. 2006 Nov;22(4):753-72, v. Review.

PMID:
17000334
30.

Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein.

Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL.

J Neurochem. 2006 Feb;96(4):950-9. Epub 2006 Jan 12.

31.

Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.

Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2004 Sep;25(5):761-9.

PMID:
15288507
32.

Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease.

Goudreau JL, Maraganore DM, Farrer MJ, Lesnick TG, Singleton AB, Bower JH, Hardy JA, Rocca WA.

Mov Disord. 2002 Nov;17(6):1305-11.

PMID:
12465073
33.

Amyloidosis presenting with intractable epistaxis and multiple cranial neuropathies.

Van Gerpen JA, Goudreau JL, Dodick DW, Gertz MA.

Neurology. 2000 Dec 12;55(11):1755-6. No abstract available.

PMID:
11113244
34.

Complications during apnea testing in the determination of brain death: predisposing factors.

Goudreau JL, Wijdicks EF, Emery SF.

Neurology. 2000 Oct 10;55(7):1045-8.

PMID:
11061269
35.

Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland.

Goudreau JL, Falls WM, Lookingland KJ, Moore KE.

Neuroendocrinology. 1995 Aug;62(2):147-54.

PMID:
8584114
37.

GABAergic regulation of tuberoinfundibular dopaminergic neurons in the male rat.

Wagner EJ, Goudreau JL, Moore KE, Lookingland KJ.

Brain Res. 1994 Oct 3;659(1-2):194-200.

PMID:
7820661
39.

Neurochemical evidence that 5-hydroxytryptaminergic neurons tonically inhibit noradrenergic neurons terminating in the hypothalamus.

Tian Y, Eaton MJ, Goudreau JL, Lookingland KJ, Moore KE.

Brain Res. 1993 Apr 2;607(1-2):215-21.

PMID:
8481797
40.
41.

Evidence that hypothalamic periventricular dopamine neurons innervate the intermediate lobe of the rat pituitary.

Goudreau JL, Lindley SE, Lookingland KJ, Moore KE.

Neuroendocrinology. 1992 Jul;56(1):100-5.

PMID:
1322505
42.

Solubility characteristics of diazepam in aqueous admixture solutions: theory and practice.

Newton DW, Driscoll DF, Goudreau JL, Ratanamaneichatara S.

Am J Hosp Pharm. 1981 Feb;38(2):179-82.

PMID:
7211883

Supplemental Content

Loading ...
Support Center